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COST-EFFECTIVENESS OF A NURSE FACILITATED SELF-MANAGEMENT
PROGRAMME FOR HEART FAILURE
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OBJECTIVES: To assess the cost-effectiveness of a nurse facilitated, cognitive be-
havioural self-management programme for patients with heart failure compared
with usual care including the un-facilitated access to the same manual, from the
perspective of the NHS. METHODS: Data were obtained from a pragmatic, multi-
centre, randomised controlled ‘open’ trial conducted in seven centres in the UK
between 2006 and 2008. Effectiveness was estimated as Quality-Adjusted Life
Years. Resource use was measured prospectively on all patients using information
provided by patients in postal questionnaires, case-note review, electronic record
review and interviews with patients. Unit costs were obtained from the literature
and applied to the relevant resource use to estimate total costs. Multiple imputa-
tion was used to handle missing data. RESULTS: There were no substantial differ-
ences in the utility scores between treatment groups in all follow-up assessments,
in the use of medication or outpatient visits and both groups report a similar
frequency of contact with health care professionals. After controlling for baseline
utility and using imputed dataset, treatment was associated with a reduction in
QALY of 0.004 and a reduction in costs of £116.2, generating an incremental cost-
effectiveness ratio of £29,036 for usual care. The probability that the intervention is
cost-effective for thresholds between £20,000 and £30,000 is around 60%.
CONCLUSIONS: There is little evidence that the addition of the intervention had
any effect on costs or outcomes. The uncertainty around both estimates of cost and
effectiveness mean that it is not reasonable to make recommendations based on
cost-effectiveness alone.
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IS IT WORTH SPENDING ANY MONEY TO DEVELOP A BIOMARKER TEST TO
OPTIMIZE STATIN TREATMENT FOR INDIVIDUALS WITH AN INTERMEDIATE
CARDIOVASCULAR RISK?
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OBJECTIVES: The 2012 European guideline on cardiovascular disease prevention
recommends statin therapy for individuals with elevated cholesterol levels and
with an intermediate risk of fatal events. However, since many individuals fall into
this category, improved discrimination is needed to prevent both cardiovascular
disease (CVD) and statin side-effects (e.g. myopathy) efficiently. We estimated the
potential cost-effectiveness of a novel biomarker test which helps to decide which
individuals with an intermediate risk should receive statins. METHODS: Prognosis
of different age- and gender-specific cohorts with an intermediate risk was simu-
lated with a literature-based Markov model to estimate the potential costs and
quality-adjusted life-years (QALYs) for four strategies: treat all with statins, treat
none with statins, treat according to the European guideline or use a test to select
individuals for statin treatment. Costs were calculated for the Netherlands using a
health care sector perspective. RESULTS: The test-first strategy was the least ex-
pensive strategy as long as a perfect test cost no more than €304 at a threshold of
€20000 per QALY gained. The perfect test-first and treat-all strategy reduced the
same number of events leading to comparable QALYs but the test generated lower
medication and drug side-effect costs. The treat-none strategy was the least cost-
effective strategy. The test needs to be very accurate and inexpensive in order to be
the most cost-effective strategy, since the impact of myopathy on cost-effective-
ness is negligible and statin costs are low. CONCLUSIONS: A test that improves
treatment decisions for individuals with an intermediate CVD risk has the poten-
tial to optimize cost-effectiveness by reducing the risk of drug side-effects and
budget impact. However, given the outcomes of this ‘early stage’ cost-effectiveness
analysis there may be limited value in developing a test with this indication. Early
stage economic evaluations can assist industry in determining whether a test is
worth developing.
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OBJECTIVES: Aortic valve replacement (AVR) is the most common heart valve op-
eration, accounting for a conspicuous part of all valve surgery performed in the
elderly. A significant subset of patients with indications for valve surgery are
deemed ineligible for conventional valve replacement because of high-risk fea-
tures or age. Prolonged aortic cross-clamping times (CCT) are an independent risk
factor for worse outcomes. Perceval S is a new aortic valve which is implanted
without need for suturing and a collapsed profile, thus allowing a significant re-
duction of cross-clamping times. Aim of this simulation study was to predict costs
and outcomes of concomitant AVR procedures associated with this new valve in 4
European countries (Italy, France, Germany, and UK), as compared to traditional
valve implants, from the cost perspective of the hospital. METHODS: A probabilis-
tic, patient-level simulation model was fully coded in WinBugs, permitting a seam-
less integration of parameter estimation and outcomes prediction, which was en-
tirely based on the associated CCTs, through published correlations. Unit cost were
retrieved from official and literature sources for all countries. Besides the incorpo-
rated probabilistic sensitivity analysis, a series of deterministic sensitivity analyses
was performed. RESULTS: The model predicts less complications with the use of
the Perceval S valve, and savings (valve cost excluded) ranging from about 6,000 €
(Italy) to about 6,700 £ (UK), mainly related to a reduction in surgery costs and
ICU/hospital bed days. Extensive sensitivity analyses confirm the robustness of
such findings. CONCLUSIONS: Reduced cross clamping times associated with the
implantation of Perceval S result in relevant savings on surgical, complication
managment and hospital stay costs in all analysed settings.
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OBJECTIVES:Heart failure patients with implantable defibrillators (ICD) frequently
undergo in office visits, placing a great burden on health care providers. Internet-
based remote device interrogation systems are being proposed in order to reduce
these visits, as well as to promptly detect and notify alert conditions. METHODS:
EVOLVO was a prospective, randomized, parallelmulticenter clinical trial compar-
ing remote ICD management with the current standard of care, assessing their
effectiveness and costs.Primary end-point: rate of cardiac or device related un-
planned emergency department (ED) or urgent in-office visits. Secondary end-
point: all health care utilizations for HF, arrhythmias or device related events;
quality of life (QoL), assessed with the Minnesota Living with Hearth Failure Ques-
tionnaire (MLHFQ), and EuroQol five Dimensions (EQ 5D). Costs were considered
from National Health Services (NHS) and patients’ and society point of view.
RESULTS:Two hundred patients (79% males; 6610years) implanted with ICD (92%
biventricular ICD) were enrolled in five Hospitals in Italy, with a follow-up of 16
months.The rate of visits considered in primary endpoint was reduced by 36% in
remote arm (75 versus 117; Incidence density: 0.59 versus 0.93 events/year;
p0.005). Overall, there were 1285 health care utilizations (secondary endpoint)
with a difference of 23% in the rates of events (4.40 events/year in remote arm vs
5.74 events/year in standard arm).The telemonitoring implied annual cost saving
per patient-year for NHS: €1962.78 for remote arm versus €2130.01 for the standard
arm. Further, remote arm gained 0.065 QALYs per patient vs standard arm. From
patients and society point of view, a cumulative costs per patient-year of 154 €
(standard arm) versus 112 € (remote arm) was assessed. CONCLUSIONS: Remote
management of chronic heart failure patients with ICD is a cost-effective solution,
with clinical and economic benefits for both health care systems and patients. A
large-scale adoption should be supported.
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Furneri G1, Scalone L2, Ciampichini R1, Cortesi PA2, Fornari C2, Madotto F2, Chiodini V2,
Cesana G2, Mantovani LG3
1Charta Foundation, Milan, Italy, 2University of Milano - Bicocca, Monza, Italy, 3Federico II
University of Naples, Naples, Italy
OBJECTIVES: To assess patients’ adherence and patterns of drug utilization
through administrative database analysis. METHODS: Using DENALI dataware-
house we detected all MS patients who, during the period January 2000 – December
2009, had at least one DMA prescription (IFN beta-1a intramuscular (IM); IFN be-
ta-1a sub-cutaneous (SC) at two different dosages: 22mcg and 44mcg; IFN beta-1b,
glatiramer acetate, natalizumab). Three drug utilization indicators, probability of
switching therapy, density of medication possession ratio (DMPR) and drug persis-
tence (measured with Kaplan-Meier method) were calculated to measure DMAs’
usage. Patients were grouped according to first DMA prescription, with the date of
first prescription being the index date. RESULTS: A total of N5,099 subjects re-
ceived at least one DMA prescription. Switching therapy occurred in 393 of 1,391
patients initiating with IFN beta-1a IM (28.3%), 482 of 964 IFN beta-1a SC 22mcg
patients (50.0%), 192 of 605 IFN beta-1a SC 44mcg patients (31.7%), 150 of 886 IFN
beta-1b patients (16.9%), 205 of 1,200 glatiramer acetate patients (17.1%), and 2 of 53
natalizumab patients (3.8%) with glatiramer acetate, 4% with natalizumab. Median
times to switch ranged from 1.8 to 2.5 years. Adherence rates were high: percentage
of patients achieving DMPR80% ranged from 78.1% to 88.9%. Probability of drug
persistence was, on average, about 80% at the end of first year of observation, being
similar across different treatments. CONCLUSIONS: Patients tend to adhere quite
well to prescribed DMA medication. However, a relevant number of patients re-
ceive therapy adjustment or modification in the short term period (after about two
years of treatment), maybe because of lack of efficacy or adverse events occur-
rence, both factors discouraging or impeding continuation. DENALI shows to be an
efficient instrument to assess prescription patterns of DMAs, although linkage with
clinical registries would remain necessary to assess reasons of switch/drop out,
and to evaluate DMAs’ efficacy.
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